Showing results (1-10 of 17) with videos related to
Sort By:
Pageof 2
Occupational Therapy in Health Care|August 15, 2013
Developing and implementing lifestyle management programs© with people with multiple sclerosisChrista Roessler, Jenny Barling, Megan Dephoff, et al.Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists|July 7, 2009
Art therapy: promoting wellbeing in rural and remote communitiesSusan SweeneyPharmaceutical Statistics|June 20, 2014
Wilcoxon's signed-rank statistic: what null hypothesis and why it mattersHeng Li, Terri JohnsonWomen and Birth : Journal of the Australian College of Midwives|April 24, 2022
The introduction of registered undergraduate students of midwifery in a tertiary hospital: Experiences of staff, supervisors, and womenLinda Sweet, Vidanka Vasilevski, Susan SweeneyJournal of Occupational and Environmental Hygiene|November 2, 2017
Assessment of occupational exposure to heat stress and solar ultraviolet radiation among groundskeepers in an eastern North Carolina university settingNicole Beck, Jo Anne G Balanay, Terri JohnsonPediatric Pulmonology|May 24, 2023
Impact of Elexacaftor-Tezacaftor-Ivacaftor on lung disease in cystic fibrosisCourtney Gushue, Mariah Eisner, Shasha Bai, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|July 23, 2014
Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutationShahid I Sheikh, Frederick R Long, Karen S McCoy, et al.JAMA Otolaryngology-- Head & Neck Surgery|September 7, 2023
Elexacaftor-Tezacaftor-Ivacaftor Therapy for Chronic Sinus Disease in Cystic FibrosisShahid Sheikh, Mai-Lan Ho, Mariah Eisner, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 17, 2023
Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: A retrospective reviewEmma L Guenther, Karen S McCoy, Mariah Eisner, et al.Pediatric Pulmonology|January 17, 2023
Clinical change 2 years from start of elexacaftor-tezacaftor-ivacaftor in severe cystic fibrosisKaren S McCoy, Jill Blind, Terri Johnson, et al.Pageof 2